These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 8786956)

  • 1. Sensitive and specific determination of the equivalence of absorption rates.
    Endrenyi L; Al-Shaikh P
    Pharm Res; 1995 Dec; 12(12):1856-64. PubMed ID: 8786956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metrics comparing simulated early concentration profiles for the determination of bioequivalence.
    Endrenyi L; Csizmadia F; Tothfalusi L; Chen ML
    Pharm Res; 1998 Aug; 15(8):1292-9. PubMed ID: 9706064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cmax/AUC is a clearer measure than Cmax for absorption rates in investigations of bioequivalence.
    Endrenyi L; Fritsch S; Yan W
    Int J Clin Pharmacol Ther Toxicol; 1991 Oct; 29(10):394-9. PubMed ID: 1748540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The duration of measuring partial AUCs for the assessment of bioequivalence.
    Endrenyi L; Csizmadia F; Tothfalusi L; Balch AH; Chen ML
    Pharm Res; 1998 Mar; 15(3):399-404. PubMed ID: 9563068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensitivity of empirical metrics of rate of absorption in bioequivalence studies.
    Ring A; Tothfalusi L; Endrenyi L; Weiss M
    Pharm Res; 2000 May; 17(5):583-8. PubMed ID: 10888310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variation of Cmax and Cmax/AUC in investigations of bioequivalence.
    Endrenyi L; Yan W
    Int J Clin Pharmacol Ther Toxicol; 1993 Apr; 31(4):184-9. PubMed ID: 8500920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absorption rate vs. exposure: which is more useful for bioequivalence testing?
    Tozer TN; Bois FY; Hauck WW; Chen ML; Williams RL
    Pharm Res; 1996 Mar; 13(3):453-6. PubMed ID: 8692741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioequivalence: performance of several measures of extent of absorption.
    Bois FY; Tozer TN; Hauck WW; Chen ML; Patnaik R; Williams RL
    Pharm Res; 1994 May; 11(5):715-22. PubMed ID: 8058642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of metabolites in bioequivalency assessment. III. Highly variable drugs with linear kinetics and first-pass effect.
    Jackson AJ
    Pharm Res; 2000 Nov; 17(11):1432-6. PubMed ID: 11205739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of direct curve comparison metrics applied to pharmacokinetic profiles and relative bioavailability and bioequivalence.
    Marston SA; Polli JE
    Pharm Res; 1997 Oct; 14(10):1363-9. PubMed ID: 9358548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The bioequivalence of highly variable drugs and drug products.
    Midha KK; Rawson MJ; Hubbard JW
    Int J Clin Pharmacol Ther; 2005 Oct; 43(10):485-98. PubMed ID: 16240706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of different indirect measures of rate of drug absorption in comparative pharmacokinetic studies.
    Lacey LF; Keene ON; Duquesnoy C; Bye A
    J Pharm Sci; 1994 Feb; 83(2):212-5. PubMed ID: 8169791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Choice of characteristics and their bioequivalence ranges for the comparison of absorption rates of immediate-release drug formulations.
    Schall R; Luus HG; Steinijans VW; Hauschke D
    Int J Clin Pharmacol Ther; 1994 Jul; 32(7):323-8. PubMed ID: 7952792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tmax: an unconfounded metric for rate of absorption in single dose bioequivalence studies.
    Basson RP; Cerimele BJ; DeSante KA; Howey DC
    Pharm Res; 1996 Feb; 13(2):324-8. PubMed ID: 8932457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of different metrics as indirect measures of rate of drug absorption from extended release dosage forms at steady-state.
    Reppas C; Lacey LF; Keene ON; Macheras P; Bye A
    Pharm Res; 1995 Jan; 12(1):103-7. PubMed ID: 7724468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Why rate of absorption inferences in single dose bioequivalence studies are often inappropriate.
    Basson RP; Ghosh A; Cerimele BJ; DeSante KA; Howey DC
    Pharm Res; 1998 Feb; 15(2):276-9. PubMed ID: 9523315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Finding T
    Han YR; Lee PI; Pang KS
    Drug Metab Dispos; 2018 Nov; 46(11):1796-1804. PubMed ID: 30135243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Esomeprazole MUPS 40 mg tablets and esomeprazole MUPS 40 mg tablets encapsulated in hard gelatine are bioequivalent.
    Talpes S; Knoerzer D; Huber R; Pfaffenberger B
    Int J Clin Pharmacol Ther; 2005 Jan; 43(1):51-6. PubMed ID: 15704615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of truncated areas in the assessment of bioequivalence of immediate release formulations of drugs with long half-lives and of Cmax with different dissolution rates.
    Sathe P; Venitz J; Lesko L
    Pharm Res; 1999 Jun; 16(6):939-43. PubMed ID: 10397617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitivity of indirect metrics for assessing "rate" in bioequivalence studies--moving the "goalposts" or changing the "game".
    Rostami-Hodjegan A; Jackson PR; Tucker GT
    J Pharm Sci; 1994 Nov; 83(11):1554-7. PubMed ID: 7891273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.